Acta Pharm. 69 (2019) 111-119
Short communication
The antitumor activity of
umbelliferone in human renal cell carcinoma via
regulation of the p110γ catalytic subunit of PI3Kγ
XUE WANG, SHUAISHUAI HUANG, XIA XIN, YU REN, GUOBIN WENG and PING WANG
1 Department of Urologic
Surgery, Ningbo Urology and Nephrology Hospital, Ningbo 315000, China
2 Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo
University, Ningbo 315000, China
3 Ningbo University, School of Medicine, Ningbo 315211, China
Accepted August 18, 2018
Published online Septemeber
18, 2018
Umbelliferone exhibits extensive pharmacological activity, including anti-immunomodulatory, anti-inflammatory and antigenotoxicity activities. However, its antitumor properties still remain unclear in human renal cell carcinoma (RCC) cells. Our results have revealed that treatment of human RCC cells (786-O, OS-RC-2, and ACHN) with umbelliferone reduced cell proliferation in a concentration-dependent manner and induced dose-dependent apoptotic events. In addition, cell cycle analysis determined that umbelliferone treatment induced cell cycle arrest in the G1 phase in a dose-dependent manner. Furthermore, western blotting analysis showed a dose-dependent decrease in Ki67, MCM2, Bcl-2, CDK2, CyclinE1, CDK4, and CyclinD1 and a dose-dependent increase in Bax in RCC cells cultured with umbelliferone. Similarly, umbelliferone exhibited a dose-dependent reduction of p110γ when using western blotting analyses. Taken together, these results provide an insight into the pharmacology regarding the potential application of umbelliferone, which contributes to cell death by decreasing p110γ protein expression.
Keywords: umbelliferone, renal cell carcinoma, p110γ, anticancer activity